Материал: Дерматовенерология (2015)

61.

van Lingen R. G., de Jong E. M., Berends M. A. et al. Good clinical response

to anti-psoriatic treatment with adalimumab and methotrexate does not inflict

a direct effect on compartmentalization of T-cell subsets: a pilot study. J Der-

matolog Treat 2008; 19: 284—287.

62.

Flytström I., Stenberg B., Svensson A., Bergbrant I. M. Methotrexate vs. ci-

closporin in psoriasis: effectiveness, quality of life and safety. A randomized

controlled trial. Br J Dermatol 2008; 158 (1): 116—121.

63.

Heydendael V. M., Spuls P. I., Opmeer B. C. et al. Methotrexate versus cyclo-

sporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003;

349 (7): 658—665.

64.

Salim A., Tan E., Ilchyshyn A., Berth-Jones J. Folic acid supplementation

during treatment of psoriasis with methotrexate: a randomized, double-blind,

placebo-controlled trial. Br J Dermatol 2006; 154 (6): 1169—1174.

65.

Chladek J., Simkova M., Vaneckova J. et al. The effect of folic acid supple-

mentation on the pharmacokinetics and pharmacodynamics of oral metho-

trexate during the remission-induction period of treatment for moderate-to-

severe plaque psoriasis. Eur J Clin Pharmacol 2008; 64 (4): 347—355.

66.

Ranjan N., Sharma N. L., Shanker V. et al. Methotrexate versus hydroxy-

carbamide (hydroxyurea) as a weekly dose to treat moderate-to-severe chronic

plaque psoriasis: a comparative study. J Dermatolog Treat 2007; 18 (5): 295—

300.

67.

Kalb R. E., Strober B., Weinstein G., Lebwohl M. Methotrexate and psoriasis:

2009 National Psoriasis Foundation Consensus Conference. J Am Acad Der-

matol 2009; 60: 824—837.

68.

Paul B. S., Momtaz K., Stern R. S. et al. Combined methotrexate—ultravio-

let B therapy in the treatment of psoriasis. J Am Acad Dermatol 1982; 7 (6):

758—762.

69.

Morison W. L., Momtaz K., Parrish J. A., Fitzpatrick T. B. Combined meth-

otrexate-PUVA therapy in the treatment of psoriasis. J Am Acad Dermatol

1982; 6 (1): 46—51.

70.

Asawanonda P., Nateetongrungsak Y. Methotrexate plus narrowband UVB

phototherapy versus narrowband UVB phototherapy alone in the treatment

of plaque-type psoriasis: a randomized, placebo-controlled study. J Am Acad

Dermatol 2006; 54 (6): 1013—1018.

71.

Mahajan R., Kaur I., Kanvar A. J. Methotrexate/narrowband UVB photo-

therapy combination vs. narrowband UVB phototherapy in the treatment of

кожи

chronic plaque-type psoriasis—a randomized single-blinded placebo-con-

trolled study. J Eur Acad Dermatol Venereol 2010; 24 (5): 595—600.

Болезни

72.

Kragballe K., Jansen C. T., Geiger J. M. et al. A double-blind comparison of

multicentre study. Acta Derm Venereol 1989; 69 (1): 35—40.

acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic

73.

Ezquerra G. M., Regana M. S., Millet P. U. Combination of acitretin and oral

calcitriol for treatment of plaquetype psoriasis. Acta Derm Venereol 2007;

87: 449—450.

74.

van de Kerkhof P. C., Cambazard F., Hutchinson P. E. et al. The effect of ad-

dition of calcipotriol ointment (50 micrograms/g) to acitretin therapy in pso-

riasis. Br J Dermatol 1998; 138: 84—89.

75.

Caproni M., Antiga E., Melani L. et al. Serum levels of IL-17 and IL-22 are

reduced by etanercept, but not by acitretin, in patients with psoriasis: a ran-

domized-controlled trial. J Clin Immunol 2009; 29: 210—214.

76.

Gisondi P., Del Giglio M., Cotena C., Girolomoni G. Combining etan-

ercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week,

randomized, controlled, investigatorblinded pilot trial. Br J Dermatol 2008;

158: 1345—1349.

77.

Caca-Biljanovska N. G., V’Lckova-Laskoska M. T. Management of guttate

and generalized psoriasis vulgaris: prospective randomized study. Croat Med J

2002; 43: 707—712.

78.

Gupta A. K., Goldfarb M. T., Ellis C. N., Voorhees J. J. Side-effect profile of

acitretin therapy in psoriasis. J Am Acad Dermatol 1989; 20: 1088—1093.

79.

Mittal R., Malhotra S., Pandhi P. et al. Efficacy and safety of combination

Acitretin and Pioglitazone therapy in patients with moderate to severe chronic

plaque-type psoriasis: a randomized, doubleblind, placebo-controlled clinical

trial. Arch Dermatol 2009; 145: 387—393.

80.

Saurat J. H., Geiger J. M., Amblard P. et al. Randomized double-blind multi-

center study comparing acitretin-PUVA, etretinate-PUVA and placebo-PUVA

in the treatment of severe psoriasis. Dermatologica 1988; 177 (4): 218—224.

81.

Lauharanta J., Geiger J. M. A double-blind comparison of acitretin and etreti-

nate in combination with bath PUVA in the treatment of extensive psoriasis.

Br J Dermatol 1989; 121: 107—112.

82.

Ozdemir M., Engin B., Baysal I., Mevlitoglu I. A randomized comparison of

acitretin-narrow-band TL-01 phototherapy and acitretinpsoralen plus ultra-

violet A for psoriasis. Acta Derm Venereol 2008; 88: 589—593.

83.

Carlin C. S., Callis K. P., Krueger G. G. Efficacy of acitretin and commercial

tanning bed therapy for psoriasis. Arch Dermatol. 2003; 139: 436—442.

84.

Ellis C. N., Fradin M. S., Messana J. M. et al. Cyclosporine for plaque-type

psoriasis. Results of a multidose, double-blind trial. N Engl J Med 1991;

324 (5): 277—284.

85.

Koo J. A randomized, double-blind study comparing the efficacy, safety and

optimal dose of two formulations of cyclosporin, Neoral and Sandimmun,

Псориаз

139: 88—95.

in patients with severe psoriasis. OLP302 Study Group. Br J Dermatol 1998;

86.

Thaci D., Brautigam M., Kaufmann R. et al. Body-weight-independent dosing

of cyclosporine micro-emulsion and three times weekly maintenance regimen

in severe psoriasis. A randomised study. Dermatology 2002; 205 (4): 383—388.

87.

Hashizume H., Ito T., Yagi H. et al. Efficacy and safety of preprandial versus

postprandial administration of low-dose cyclosporin microemulsion (Neoral)

in patients with psoriasis vulgaris. J Dermatol 2007; 34: 430—434.

88.

Yoon H. S., Youn J. I. A comparison of two cyclosporine dosage regimens for

the treatment of severe psoriasis. J Dermatolog Treat 2007; 18 (5): 286—290.

89.

Mahrle G., Schulze H. J., Farber L. et al. Low-dose short-term cyclosporine

versus etretinate in psoriasis: improvement of skin, nail, and joint involve-

ment. J Am Acad Dermatol 1995; 32 (1): 78—88.

90.

Elder C. A., Moore M., Chang C. T. et al. Efficacy and pharmacokinetics of

two formulations of cyclosporine A in patients with psoriasis. J Clin Pharma-

col 1995; 35 (9): 865—875.

91.

Finzi A. F. Mozzanica N., Pigatto P. D. et al. Cyclosporine versus etretinate:

Italian multicentre comparative trial in severe psoriasis. Dermatology 1993;

187 (Suppl 1): 8—18.

92.

Gisondi P., Del Giglio M. D., Francesco V. et al. Weight loss improves the

response of obese patients with moderate-to-severe chronic plaque psoriasis to

low-dose cyclosporine therapy: a randomized, controlled, investigatorblinded

clinical trial. Am J Clin Nutr 2008; 88: 1242—1247.

93.

Laburte C., Grossman R., Abi-Rached J. et al. Efficacy and safety of oral cy-

closporin A (CyA; Sandimmun) for long-term treatment of chronic severe

plaque psoriasis. Br J Dermatol 1994; 130 (3): 366—375.

94.

Levell N. J., Shuster S., Munro C. S., Friedmann P. S. Remission of ordinary

psoriasis following a short clearance course of cyclosporin. Acta Derm Vene-

reol 1995; 75 (1): 65—69.

95.

Meffert H., Brautigam M., Farber L., Weidinger G. Low dose (1.25 mg/kg)

cyclosporin A: treatment of psoriasis and investigation of the influence on lipid

profile. Acta Derm Venereol 1997; 77 (2): 137—141.

96.

Reitamo S., Spuls P., Sassolas B. et al. Efficacy of sirolimus (rapamycin) ad-

ministered concomitantly with a subtherapeutic dose of cyclosporin in the

treatment of severe psoriasis: a randomized controlled trial. Br J Dermatol

2001; 145: 438—445.

97.

Agnew K. L., Bunker C. B. Multiple cutaneous squamous carcinoma in a

psoriatic associated with ciclosporin, alcohol abuse and ultraviolet radiation

кожи

exposure which were suppressed by acitretin. J Eur Acad Dermatol Venereol

2003; 17: 113—114.

Болезни

98.

Paul C. F., Hо  V. C., McGeown C. et al. Risk of malignancies in psoriasis pa-

120: 211—216.

tients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol 2003;

99.

Antoni C., Krueger G. G., de Vlam K., Birbara et al. Infliximab improves signs

and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum

Dis 2005; 64: 1150—1157.

100.

Gottlieb A. B., Evans R., Li S. et al. Infliximab induction therapy for patients

with severe plaque-type psoriasis: a randomized, double-blind, placebo-con-

trolled trial. J Am Acad Dermatol 2004; 51 (4): 534—542.

101.

Reich K., Nestle F. O., Papp K. et al. Infliximab induction and maintenance

therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-

blind trial. Lancet 2005; 366 (9494): 1367—1374.

102.

Reich K., Nestle F. O., W. Y. et al. Infliximab treatment improves productivity

among patients with moderate-to-severe psoriasis. Eur J Dermatol 2007; 17:

381—386.

103.

Chaudhari U., Romano P., Mulcahy L. D. et al. Efficacy and safety of inflix-

imab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001;

357: 1842—1847.

104.

Lecluse L. L., Piskin G.,. Mekkes J. R. et al. Review and expert opinion on

prevention and treatment of infliximab-related infusion reactions. Br J Der-

matol 2008; 159: 527—536.

105.

Maini R., St Clair E. W., Breedveld F. et al. Infliximab (chimeric anti-tumour

necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid ar-

thritis patients receiving concomitant methotrexate: a randomised phase III

trial. ATTRACT Study Group. Lancet 1999; 354: 1932—1939.

106.

Gordon K. B., Langley R. G., Leonardi C. et al. Clinical response to adalim-

umab treatment in patients with moderate to severe psoriasis: double-blind,

randomized controlled trial and open-label extension study. J Am Acad Der-

matol 2006; 55 (4): 598—606.

107.

Menter A., Tyring S. K., Gordon K. et al. Adalimumab therapy for moderate

to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Der-

matol 2008; 58: 106—115.

108.

Gordon K., Papp K., Poulin Y. et al. Long-term efficacy and safety of adali-

mumab in patients with moderate to severe psoriasis treated continuously over

3 years: results from an open-label extension study for patients from REVEAL.

J Am Acad Dermatol 2012; 66 (2): 241—251.

109.

Papp K, Menter A, Poulin Y. et al. Long-term outcomes of interruption and

retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis

of REVEAL and the open-label extension study. J Eur Acad Dermatol Vene-

reol 2013; 27 (5): 634—642.

110.

Leonardi C. L., Kimball A. B., Papp K. A. et al. Efficacy and safety of

Псориаз

ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients

controlled trial (PHOENIX 1). Lancet 2008; 371 (9625): 1665—1674.

with psoriasis: 76-week results from a randomised, double-blind, placebo-